Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Nuanchan Mungkhunkhamchaw

Khon Kaen University, Thailand

Title: Pooled Cryoprecipitate Ready to use

Biography

Biography: Nuanchan Mungkhunkhamchaw

Abstract

Introduction: The pooled component represents a source of concentrated FVIII:C, von Willebrand factor, fibrinogen, FXIII and fibronectin from primary cryoprecipitate components derived from units of fresh frozen plasma. Plasma should be selected from male donors or consideration should be given to screening female donors for HLA/HNA antibodies, as a TRALI risk reduction measure. For storage, cryoprecipitate pooled should be rapidly frozen to a core temperature of –25 ℃ or below within 2 hours of preparation.

Method: Cryoprecipitate was prepared by standard conventional method the male unit was selected for re-suspend cryoprecipitate 120-150 mL per pool. Five to six iso-blood group were pooled by connecting device within 5 minutes. The pooled cryoprecipitate were rapid frozen by -50 ℃ blast. The evaluated of pooled were determine for factor VIII and fibrinogen.

Result: Pooled cryoprecipitate from 5 units by A, B, O blood group were determination of factor VIII and fibrinogen found 109/282, 136/358 and 70/288, respectively. Six units pooled were found 113/342, 139/318 and 78.5/259, respectively. Pooled no group five units in plasma B and AB were found 143/400 and 114/400.

Conclusion: Pooled cryoprecipitate seem useful for routine. The yield of Factor VIII are acceptable in A, B and AB. Blood group O is recommend for better mix with other group and should be resuspend in plasma B or A.